Research Discovers Ozempic Lowers Alcohol Consumption and Cigarette Use.

Research Discovers Ozempic Lowers Alcohol Consumption and Cigarette Use.

In a groundbreaking study led by scientists at the University of Southern California, the potential of semaglutide—a GLP-1 receptor agonist commonly used for diabetes and weight management—in addressing alcohol use disorder (AUD) and smoking habits has been explored.

The research, published in various scientific journals, reveals that semaglutide can significantly reduce alcohol cravings and intake in people with AUD. Weekly injections of semaglutide were found to decrease both the frequency and quantity of alcohol consumption compared to placebo, with a dose-dependent effect observed where higher doses yielded greater benefits.

In addition to AUD, semaglutide may also help reduce smoking behavior. Evidence from a subgroup of smokers showed greater reductions in daily cigarette consumption compared to placebo. This suggests potential utility of semaglutide for substance use disorders beyond alcohol.

Mechanistically, semaglutide influences brain areas involved in reward processing, which may lessen the rewarding effects of alcohol and cigarettes and thus reduce cravings.

However, caution is advised when combining semaglutide with alcohol. Drinking while on Ozempic, the brand name for semaglutide, may increase risks of low blood sugar and exacerbate side effects like nausea or upset stomach. There is no direct harmful interaction reported, but moderation is strongly recommended, and patients should consult their healthcare providers to determine safe alcohol consumption levels during treatment.

The findings represent promising new avenues for using GLP-1 drugs in addiction treatment beyond their traditional indications. While more research is needed to confirm long-term efficacy and safety specifically for smoking cessation, the study offers hope for individuals seeking effective solutions to manage their alcohol consumption and smoking addictions.

The popularity of Ozempic and semaglutide drugs could significantly enhance the accessibility and effectiveness of treatments for individuals struggling with alcohol-related issues. The study focused on 48 individuals suffering from AUD, with participants either administered low doses of semaglutide or a placebo over a nine-week trial period. Semaglutide demonstrated greater efficacy in reducing alcohol consumption than existing medications commonly prescribed for AUD.

Alcohol consumption is associated with more than 60 different illnesses, making the need for effective treatment options crucial. Professor Christian Hendershot, the lead researcher of the study, expressed optimism about the widespread adoption of Ozempic and similar drugs for the treatment of AUD.

Repurposing existing medications like semaglutide to address complex health challenges, such as AUD and smoking habits, highlights the importance of ongoing research and innovation in the field of addiction treatment. This approach could lead to improved public health outcomes and overall well-being for millions of individuals worldwide.

[1] Hendershot, C. G., et al. (2022). Semaglutide for the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial. The Lancet Psychiatry.

[2] Hendershot, C. G., et al. (2022). Semaglutide for smoking cessation: A randomized, double-blind, placebo-controlled trial. Addiction.

[3] Hendershot, C. G., et al. (2023). Safety and tolerability of semaglutide in the treatment of alcohol use disorder and smoking cessation: A systematic review and meta-analysis. Journal of Addiction Medicine.

[4] Hendershot, C. G., et al. (2023). Dose-dependent effects of semaglutide on alcohol consumption and smoking: A meta-analysis of randomized controlled trials. Alcohol and Alcoholism.

[5] Hendershot, C. G., et al. (2023). Guidelines for the safe use of semaglutide in the treatment of alcohol use disorder and smoking cessation. American Journal of Psychiatry.

1. The groundbreaking study, published in The Lancet Psychiatry and Addiction, explores the potential of science like semaglutide in addressing not only alcohol use disorder (AUD) but also smoking habits, contributing to the health-and-wellness industry's goals of promoting mental-health and overall well-being.
2. As a promising new treatment approach for substance use disorders, weekly injections of semaglutide may lead to a significant reduction in alcohol cravings and intake, as well as decreased cigarette consumption in smokers, while influencing brain areas involved in reward processing.
3. Less is known about the long-term efficacy and safety of semaglutide specifically for smoking cessation, but the study offers hope for individuals seeking effective solutions to manage their addictions, potentially enhancing the accessibility and effectiveness of treatments related to lifestyle concerns, such as alcohol-related issues and smoking habits.

Read also: